Hanmi Pharmaceutical Confirms Initial Efficacy of Two Cancer Drugs in Global Phase 1 Trials

Hanmi Pharmaceutical's two cancer drug candidates have shown responses in some patients to suppress cancer in global Phase 1 clinical trials. The safety profile has also been manageable, indicating a potential acceleration in subsequent trials.
 
On November 17, Hanmi Pharmaceutical announced that it presented the Phase 1 clinical trial results of the targeted cancer drug 'HM97662' and the immuno-oncology drug 'BH3120' in a poster session at the European Society for Medical Oncology (ESMO 2026) held in Madrid, Spain, from October 23 to 27.
 
HM97662 is a drug that simultaneously inhibits the proteins EZH1 and EZH2, which regulate gene expression. Abnormal functioning of these two proteins can lead to cancer cell growth. It has been pointed out that inhibiting only EZH2 may allow EZH1 to compensate, potentially reducing efficacy or leading to resistance, making the dual inhibition approach a viable alternative.
 
In this trial, patients were randomly assigned to receive doses of 200 mg and 300 mg to determine the appropriate dosage. Both doses exhibited manageable side effects. Cancer suppression responses were observed in patients with ovarian clear cell carcinoma harboring ARID1A gene mutations and in patients with chordoma who had lost the SMARCB1 gene. Chordoma is a rare malignant tumor that occurs in the spine or the base of the skull. Responses were also noted in patients with mesothelioma and uterine sarcoma with SMARCA4 deficiency. Hanmi Pharmaceutical plans to further evaluate safety and efficacy in a dose expansion phase targeting solid tumor patients with chromatin regulation abnormalities.
 
BH3120 is an immuno-oncology drug utilizing Hanmi Pharmaceutical's dual antibody platform 'Pentambody.' It binds simultaneously to PD-L1 on cancer cell surfaces and to 4-1BB on immune cells (T cells), facilitating the attack of immune cells on cancer cells. Previous candidates targeting 4-1BB faced development halts or limitations due to insufficient efficacy or liver toxicity issues. BH3120 is designed to elicit immune responses only in tumors with PD-L1, focusing on reducing side effects in normal tissues.
 
In this Phase 1 dose escalation study involving 45 patients with advanced solid tumors, no dose-limiting toxicities were observed across all dosage groups. The maximum tolerated dose was not reached. There were no severe cases of liver toxicity, which had been a weakness of existing 4-1BB class drugs. Initial cancer suppression responses were noted in various solid tumor patients.
 
Lee Moon-hee, head of clinical development at Hanmi Pharmaceutical, stated, "We have confirmed differentiated competitiveness in the Phase 1 clinical data of HM97662 and BH3120," adding, "We plan to develop these as treatments that can improve clinical outcomes for patients in areas with high unmet needs."
 
Meanwhile, Hanmi Pharmaceutical achieved cumulative sales of 1.2 trillion won in the third quarter.
 
On October 27, Hanmi Pharmaceutical announced its preliminary consolidated results for the third quarter, reporting sales of 377.4 billion won, operating profit of 37.8 billion won, and net profit of 14 billion won. Sales increased by 4.2% compared to the same period last year, while operating profit and net profit decreased by 31.3% and 69.1%, respectively. Cumulative sales for the third quarter totaled 1.2376 trillion won.




* This article has been translated by AI.